2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Stem Cell/Wnt
  4. Casein Kinase
  5. Casein Kinase Isoform
  6. Casein Kinase Inhibitor

Casein Kinase Inhibitor

Casein Kinase Inhibitors (36):

Cat. No. Product Name Effect Purity
  • HY-115519
    (E/Z)-GO289
    		Inhibitor 99.60%
    (E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC50=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function.
  • HY-145939
    BAY-888
    		Inhibitor 98.35%
    BAY-888 is an orally active CSNK1A1 and CSNK1D inhibitor with IC50 of 1.5 nM and 5.5 nM, respectively. BAY-888 has antitumor activity.
  • HY-114858
    Epiblastin A
    		Inhibitor 99.51%
    Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC50s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1.
  • HY-159646
    BMS-986397
    		Inhibitor
  • HY-158975
    VRK1/CK1-IN-1
    		Inhibitor 98.69%
    VRK1/CK1-IN-1 (compound 36) is a dual inhibitor of vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1), with the Ki of 37.9 nM for VRK1 and IC50s of 17 nM and 15 nM for δ and ε isoforms of CK1, respectively.
  • HY-145940
    BAY-204
    		Inhibitor 98.87%
    BAY-204 is an inhibitor of Casein kinase 1 alpha and delta (CSNK1α and δ) useful for the research of proliferative disorders.
  • HY-120084
    BTX161
    		Inhibitor 98.91%
    BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.
  • HY-148491
    CSNK1-IN-2
    		Inhibitor 98.20%
    CSNK1-IN-2 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC50 values of 2.52 μM. CSNK1-IN-2 can be used for the research of proliferative disorders.
  • HY-111378
    Casein Kinase II Inhibitor IV
    		Inhibitor ≥98.0%
    Casein Kinase II Inhibitor IV is a potent, ATP-competitive of casein kinase II inhibitor with an IC50 of 9 nM. Casein Kinase II Inhibitor IV ia also a human keratinocytes (NHEK) differentiation inducer.
  • HY-153905
    Casein kinase 1δ-IN-6
    		Inhibitor 99.93%
    Casein kinase 1δ-IN-6 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 23 nM. Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory properties both in vitro and in vivo. Casein kinase 1δ-IN-6 is a promising drug candidate and can be used for neurodegenerative diseases research.
  • HY-N3127
    Orobol
    		Inhibitor 99.28%
    Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2/KDR/Flk-1, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ).
  • HY-157478
    CSNK2A-IN-1
    		Inhibitor 98.46%
    CSNK2A-IN-1 (compound 7C) is a selective CSNK2A inhibitor. CSNK2A-IN-1 has antiviral activity and improved selectivity over PIM3.
  • HY-148489
    CSNK1-IN-1
    		Inhibitor 99.23%
    CSNK1-IN-1 is a CSNK1A1 inhibitor. CSNK1-IN-1 has inhibitory activity for CSNK1A1 kinase with IC50 values of 21 μM. CSNK1-IN-1 can be used for the research of proliferative disorders.
  • HY-148318
    CK2α-IN-1
    		Inhibitor 98.34%
    CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies.
  • HY-111378A
    Casein Kinase II Inhibitor IV hydrochloride
    		Inhibitor
    Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation.
  • HY-14393S
    Emodin-d4
    		Inhibitor
    Emodin-d4 is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].
  • HY-156913
    Casein kinase 1δ-IN-13
    		Inhibitor
    Casein kinase 1δ-IN-13 (compound 401) is a Casein kinase 1δ inhibitor. Casein kinase 1δ-IN-13 can be used in neurodegenerative disease research.
  • HY-155987
    CK2-IN-8
    		Inhibitor
    CK2-IN-8 (compound 5c) is a CK2 inhibitor with IC50 >33 μM.
  • HY-12570
    CK2-IN-9
    		Inhibitor
    CK2-IN-9 is a potent and selective inhibitor of CK2 kinase with an IC50 of 3 nM. CK2-IN-9 reduces Wnt reporter activity with an IC50 of 75 nM. CK2-IN-9 has low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) properties in rat.
  • HY-162078
    Antiproliferative agent-46
    		Inhibitor
    Antiproliferative agent-46 (compound 5e) is an inhibitor of the casein kinase-2 enzyme (CK2) receptor. Antiproliferative agent-46 has a potent antiproliferative activity with an IC50 value of 5.75 μM on the U87 cell line.